In a landmark study poised to accelerate our understanding of Parkinson’s disease, researchers have employed spatial multi-omics to unravel region-specific molecular signatures in a widely used 6-hydroxydopamine (6-OHDA) rat model. Parkinson’s disease, a neurodegenerative disorder characterized predominantly by motor deficits, has long eluded precise molecular mapping at the regional brain level. The recent publication by Lee, Shon, Lee, and colleagues in npj Parkinson’s Disease offers a high-resolution, multidimensional molecular atlas that sheds light on the underlying complexity and heterogeneity of Parkinson’s disease pathology.
The 6-OHDA model, a classical experimental paradigm, induces selective dopaminergic neuron degeneration mimicking key symptomatic and pathological features of Parkinson’s. However, previous analyses were limited by a lack of spatial context, which left critical gaps in understanding how Parkinsonian pathology manifests and progresses across distinct brain regions. By integrating cutting-edge spatial transcriptomics, proteomics, and metabolomics, the team achieved an unprecedented multilayered molecular characterization of affected brain regions. This holistic approach provides new vistas into the spatial heterogeneity of disease-related molecular changes.
Spatial multi-omics refers to the simultaneous acquisition of diverse molecular data—such as RNA transcripts, proteins, and metabolites—mapped directly within tissue architecture. This integrative strategy uncovers not only presence but also cellular and regional localization, an essential feature for unraveling neurodegenerative processes that unfold in complex brain circuitry. Lee and colleagues leveraged this methodology to dissect the subtleties of molecular alterations in the striatum, substantia nigra, and adjacent regions following 6-OHDA lesioning.
One of the most striking findings of the study was the identification of distinct molecular signatures unique to each brain region examined. In the substantia nigra pars compacta, the primary site of dopaminergic neuron loss in Parkinson’s, alterations in gene expression related to mitochondrial dysfunction and oxidative stress were predominant. These changes corroborate decades of research implicating mitochondria as central players in Parkinsonian neurodegeneration. However, the spatial resolution of this study affirms these phenomena at a cellular neighborhood level, implicating localized microenvironment factors in modulating vulnerability.
Interestingly, neighboring regions such as the dorsal striatum showed a different molecular profile dominated by dysregulation of synaptic signaling and neurotransmitter metabolism pathways. This spatial divergence underscores the complexity of pathology propagation, suggesting that while neuron death is a hallmark, altered network connectivity and signaling may drive secondary disease features. The crosstalk between regions, now visible at molecular resolution, could inform therapeutic targeting strategies aimed at both neuron preservation and circuit function restoration.
Proteomic data layers added significant depth by revealing protein abundance changes that did not always parallel transcriptomic trends, highlighting the importance of post-transcriptional regulation in disease progression. Some proteins involved in neuroinflammation and cellular stress responses were markedly elevated in perilesional zones, correlating with local microglial activation patterns visualized via spatial proteomics. This further supports emerging views that neuroinflammation contributes critically to Parkinson’s pathophysiology and may vary regionally.
Metabolomic profiling complemented these findings by uncovering metabolic signatures indicative of altered energy homeostasis and impaired redox balance within specific brain areas. For instance, the accumulation of certain oxidative metabolites was spatially linked to dopaminergic neuron loss sites, providing a biochemical readout of cellular distress. The integration of these metabolite data with transcript and protein maps allows for a systems-level understanding of neurodegeneration grounded not only in molecular identity but also in metabolic function.
Beyond just cataloging molecular alterations, the study also employed advanced computational modeling to infer potential mechanistic pathways disrupted across brain regions. Network analyses revealed regionally distinct hubs of perturbed gene-protein-metabolite interactions, pinpointing candidate molecular targets that might modulate disease vulnerability or progression. These insights pave the way for future investigations into novel neuroprotective or disease-modifying therapies that consider spatial molecular context.
The technical achievements of this work are equally remarkable. Utilizing next-generation spatial omics platforms, the researchers generated multi-layered maps with cellular resolution over millimeter-scale brain tissue areas. This scale and granularity had been a formidable challenge with earlier techniques. Moreover, the integration of diverse omic modalities with histological imaging established a comprehensive workflow applicable beyond Parkinson’s, potentially benefiting broader neurodegenerative disease research.
This study represents a paradigm shift by demonstrating the feasibility and power of spatial multi-omics in dissecting brain pathologies with anatomical precision. It highlights the necessity of studying neurodegeneration not as a uniform process but as a spatially nuanced mosaic of molecular events. Such insights are critical for translating basic science into precision medicine, wherein therapies can be tailored to regional pathological features rather than generic whole-brain approaches.
Given the complexity of Parkinson’s disease and its clinical variability, spatially resolved molecular data will be invaluable for biomarker discovery. Identifying region-specific signatures could aid in developing imaging agents or fluid biomarkers reflecting localized injury processes, finally providing tools for early diagnosis and monitoring therapy responses. This spatial dimension is currently missing from most biomarker development pipelines.
The emphasis on the 6-OHDA model in this study is also notable. Despite being a decades-old experimental model, its full potential has been limited by lack of multidimensional characterization. By applying spatial multi-omics, the researchers revitalize this model’s relevance, demonstrating how it can be harnessed to uncover pathophysiological mechanisms with unprecedented clarity. This sets a benchmark for model system evaluation that other neurodegeneration research programs will likely emulate.
Future directions inspired by this work could include applying similar spatial multi-omics approaches to human postmortem Parkinson’s brain tissues. While more technically challenging due to tissue preservation issues, such efforts could validate the rodent findings and directly connect them to human pathology. Additionally, longitudinal studies mapping molecular dynamics over disease stages could further refine our understanding of Parkinson’s onset and progression.
In summary, Lee and colleagues deliver a tour de force spatial multi-omics study that unpacks the molecular complexity of Parkinson’s disease in a classical 6-OHDA rodent model. Their integrative and spatially aware approach exposes the molecular heterogeneity within and between affected brain regions, implicating pathways ranging from mitochondrial dysfunction to neuroinflammation and synaptic dysregulation. This multidimensional mapping not only enriches basic science paradigms but heralds translational avenues for targeted therapeutics and precision diagnostics. As neuroscience moves toward ever more refined molecular cartography, studies like this will be foundational in bridging cellular pathology to clinical reality.
This work exemplifies the unifying power of spatial multi-omics to transform our view of neurodegenerative disorders from diffuse conditions to anatomically and molecularly dissectible diseases. The viral potential of this paradigm lies in its ability to inspire cross-disciplinary research, link molecular neuroscience with clinical neurology, and ultimately improve outcomes for Parkinson’s patients. By turning the spotlight on brain regional molecular intricacies, Lee et al. illuminate new paths forward in the quest against Parkinson’s disease.
Subject of Research: Molecular and spatial characterization of Parkinson’s disease pathology using the 6-OHDA rat model.
Article Title: Spatial multi-omics reveals region-specific molecular signatures in a 6-OHDA model of Parkinson’s disease.
Article References:
Lee, S.Y., Shon, H.K., Lee, A.C. et al. Spatial multi-omics reveals region-specific molecular signatures in a 6-OHDA model of Parkinson’s disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01433-5
Image Credits: AI Generated
